NCT07175662View on ClinicalTrials.gov

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

August 30, 2027

Conditions
High-grade Squamous Intraepithelial Lesion (HSIL)
Interventions
BIOLOGICAL

NWRD08 administered by electroporation

NWRD08 delivered via IM injection + electroporation using TERESA device

BIOLOGICAL

Placebo administered by electroporation

Placebo delivered via IM injection + electroporation using TERESA device

Trial Locations (5)

100021

Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing

100026

Beijing Obstetrics and Gynecology Hospital, Beijing

100034

Peking University First Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

030001

The Second Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Newish Biotech (Wuxi) Co., Ltd.

INDUSTRY